Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow-derived mesenchymal stem cell therapy for alcoholic liver cirrhosis-related hepatic failure
KCT0000266Phase 2Completed
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Sep 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in alcoholic cirrhosis and hepatic failure, sponsored by Pharmicell Co., Ltd. Started Sep 2009; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
alcoholic cirrhosishepatic failure
Beyond the preview
Go deeper on KCT0000266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000266.